Logo image of ANVS

ANNOVIS BIO (ANVS) Stock Fundamental Analysis

NYSE:ANVS - New York Stock Exchange, Inc. - US03615A1088 - Common Stock - Currency: USD

2.68  0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ANVS. ANVS was compared to 551 industry peers in the Biotechnology industry. While ANVS has a great health rating, there are worries on its profitability. ANVS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ANVS has reported negative net income.
In the past year ANVS has reported a negative cash flow from operations.
ANVS had negative earnings in each of the past 5 years.
In the past 5 years ANVS always reported negative operating cash flow.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ANVS has a Return On Assets of -108.69%. This is in the lower half of the industry: ANVS underperforms 78.40% of its industry peers.
Looking at the Return On Equity, with a value of -120.81%, ANVS is in line with its industry, outperforming 41.92% of the companies in the same industry.
Industry RankSector Rank
ROA -108.69%
ROE -120.81%
ROIC N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ANVS has been increased compared to 1 year ago.
Compared to 5 years ago, ANVS has more shares outstanding
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ANVS has an Altman-Z score of 2.31. This is not the best score and indicates that ANVS is in the grey zone with still only limited risk for bankruptcy at the moment.
ANVS has a better Altman-Z score (2.31) than 70.42% of its industry peers.
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.31
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 10.68 indicates that ANVS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.68, ANVS belongs to the top of the industry, outperforming 80.40% of the companies in the same industry.
ANVS has a Quick Ratio of 10.68. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ANVS (10.68) is better than 80.40% of its industry peers.
Industry RankSector Rank
Current Ratio 10.68
Quick Ratio 10.68
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

1

3. Growth

3.1 Past

ANVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.52%, which is quite impressive.
EPS 1Y (TTM)59.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.00% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.33%
EPS Next 2Y4.82%
EPS Next 3Y9.28%
EPS Next 5Y15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

0

4. Valuation

4.1 Price/Earnings Ratio

ANVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.82%
EPS Next 3Y9.28%

0

5. Dividend

5.1 Amount

No dividends for ANVS!.
Industry RankSector Rank
Dividend Yield N/A

ANNOVIS BIO

NYSE:ANVS (8/5/2025, 3:00:09 PM)

2.68

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners16.03%
Inst Owner Change-0.03%
Ins Owners14.51%
Ins Owner Change2.81%
Market Cap52.23M
Analysts80
Price Target14.54 (442.54%)
Short Float %14.81%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.79%
Min EPS beat(2)-27.55%
Max EPS beat(2)11.97%
EPS beat(4)2
Avg EPS beat(4)-11.56%
Min EPS beat(4)-80.79%
Max EPS beat(4)50.15%
EPS beat(8)4
Avg EPS beat(8)-8.16%
EPS beat(12)6
Avg EPS beat(12)-25.22%
EPS beat(16)8
Avg EPS beat(16)-30.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-24%
PT rev (3m)-54.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.94%
EPS NY rev (1m)4.76%
EPS NY rev (3m)11.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.17
P/tB 2.17
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.69%
ROE -120.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.68
Quick Ratio 10.68
Altman-Z 2.31
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
EPS Next Y10.33%
EPS Next 2Y4.82%
EPS Next 3Y9.28%
EPS Next 5Y15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.18%
EBIT Next 3Y-44.37%
EBIT Next 5Y22.26%
FCF growth 1Y11.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.42%
OCF growth 3YN/A
OCF growth 5YN/A